A part of Watch Media

MedWatchSunday2 April 2023

  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
Foto: Rob Acket/ema

CHMP recommends nine drugs in March

A total of 21 new drugs have been recommended for approval in 2023.
  • CHMP recommends eight drugs in February – rejects Covid-19 pill
  • J&J drops RSV vaccine after two competitors get closer to approval

For subscribers

Foto: George Frey

Novo Nordisk helps Canada resolve Ozempic issue

For subscribers

Minister for the Interior and Health of Denmark Sophie Løhde must answer questions concerning Novo Nordisk's funding of a Danish patient group | Photo: Ida Marie Odgaard

Danish health minister to answer questions about Novo Nordisk sponsorship of patient group

For subscribers

Foto: Bavarian Nordic / Pr

Former Bavarian Nordic chairman sees opportunities in Johnson & Johnson's RSV exit

For subscribers

Foto: Valdemar Ren

New study says AstraZeneca drug rarely leads to RSV mutations

For subscribers

Bluebird Bio expects delay on FDA sickle cell drug application

For subscribers

  • Foto: Ida Marie Odgaard/Ritzau Scanpix

    WHO mulls over labeling obesity drugs as essential medicines

    A request to consider a Novo Nordisk obesity drug as an essential medicine was submitted by three doctors and a scientist in the US.

    For subscribers

  • Foto: Tidsvilde Stine/Ritzau Scanpix

    Watchdog looking into Novo Nordisk sponsorship of patient group

    The Danish drugmaker has until mid-April to produce materials related to a case concerning a sponsorship of a Danish patient organization.

    For subscribers

  • Foto: Dado Ruvic/Reuters/Ritzau Scanpix

    J&J drops RSV vaccine after two competitors get closer to approval

    Both Pfizer and GSK recently won the approval of an FDA panel for their respective vaccines, and Johnson & Johnson now bows out of the race to get a vaccine against the lung infection.

    For subscribers

  • Lene Skole, CEO of the Lundbeck Foundation | Foto: Gregers Tycho

    Lundbeck and ALK boost the Lundbeck Foundation's operating result

    Though the foundation’s investment activities hemorrhaged DKK 2bn over 2022, fine performances by pharmaceutical companies Lundbeck and ALK help lift the operating profit.

    For subscribers

  • Foto: Marcus Brandt/AP/Ritzau Scanpix

    AstraZeneca retires diabetes drug in the Nordics

    The market for an 11-year-old diabetes treatment has disappeared as new treatments have come out.

    For subscribers

  • Foto: Ida Marie Odgaard

    Americans prevented from buying Ozempic in British Columbia

    ”We don’t want to become a supplier for the US market,” says health minister in British Columbia.

    For subscribers

  • Foto: Martin Lehmann

    Ferring closes research institute, fires staff

    An expansion program had just been completed for the San Diego-based research unit that is now shutting down.

    For subscribers

  • Anders Schelde, chief investment and financial officer at AkademikerPension, hopes it will become common practice that companies halt bonus programs when the bonus-allocated stock wealth of CEOs reach a certain level. | Foto: PR/MP Pension

    Danish pension fund argues for capping Genmab CEO's pay

    Once the bonus-issued stock wealth of a CEO hits a certain level, bonuses should stop, says AkademikerPension.

    For subscribers

  • Antibiotic Dicillin has infected Danish and Icelandic patients Antibiotikummet Dicillin har smittet både danskere og islændinge med multiresistente bakterier, som patienterne sandsynligvis skal leve med resten af livet. | Foto: Lægemiddelstyrelsen / Pr

    Sandoz severs ties with European CMO – Dicillin permanently withdrawn from market

    Sandoz ends its collaboration with the secret CMO that made the contaminated antibiotic product and cannot rule out other drugs could be infected with multi-resistant bacteria.

    For subscribers

  • Foto: Zealand Pharma / Pr

    Zealand Pharma presents positive early-stage results for weight-loss candidate

    The Danish biotech company is encouraged, although more testing will be needed ”to fully assess the clinical potential” of a new obesity treatment candidate.

    For subscribers

  • Både danskere og islændinge har nu multiresistente bakterier i kroppen efter at have spist antibiotikummet Dicillin. | Foto: Lægemiddelstyrelsen / Pr

    Denmark: Violation of good manufacturing practice is source of contaminated antibiotic

    The Danish Medicines Agency seeks to bring the matter to European inspectors to increase awareness of potential problems in the future.

    For subscribers

  • Foto: Novo Nordisk / Pr

    Analyst: New Novo Nordisk data sets the bar high for diabetes pills

    Despite promising results, one analyst thinks patients will have to wait for higher doses of diabetes pill Rybelsus until 2025. 

    For subscribers

  • Foto: Tuala Hjarnø / Genmab / Pr

    Genmab promotes senior VP for strategy to executive management

    Martine van Vugt, a veteran at Genmab, has risen through the ranks.

    For subscribers

  • Foto: Christopher Due Karlsson / Medwatch

    Novo Nordisk chair boasts competitive production advantage

    The Danish drugmaker’s chair says the company’s production facilities makes it one to watch, and Novo Nordisk is only increasing its investments into expanding capacity in 2023.

    For subscribers

  • Foto: Tidsvilde Stine/Ritzau Scanpix

    Novo Nordisk enters collaboration with AI-driven drug discovery company

    Insilico Medicine has developed an AI-driven platform that will help the Danish drugmaker identify targets against liver fibrosis. 

    For subscribers

  • California is taking a USD 50m step toward its ambition to make its own insulin products | Foto: George Frey/Reuters/Ritzau Scanpix

    California moves forward with making biosimilar insulin

    The state has entered a contract with generic drugmaker Civica to make insulin products that are interchangeable with those of Novo Nordisk, Sanofi, and Eli Lilly. 

    For subscribers

  • Glenn Saldanha is chairman at the board of Glenmark | Foto: Danish Siddiqui/Reuters/Ritzau Scanpix

    Indian generic drugmaker to launch Leo Pharma copycat drug in US

    Generic drugmaker Glenmark has received 180-day generic drug exclusivity on one of Leo Pharma’s inventions.

    For subscribers

  • Foto: Ida Marie Odgaard/Ritzau Scanpix

    Obesity drug hit makes Novo Nordisk more valuable than Nestle

    The Danish drugmaker has climbed from seventh to second place of Europe’s most valuable firms in just two years. 

    For subscribers

  • Initial probes pointed to the contamination coming from the capsules containing Dicillin, or the drug's packaging | Foto: Lægemiddelstyrelsen / Pr

    Production at contaminated CMO continues – authorities deny further risks

    The Danish Medicines Agency says shutting down the one production line specifically making the contaminated Dicillin is adequate, although the root cause is still unknown.

    For subscribers

  • Foto: Novo Nordisk / Pr

    Novo Nordisk reaches primary endpoint in phase III study of oral semaglutide

    The study tested 25mg and 50mg doses, and both showed a higher efficacy after 52 weeks compared to 14mg.

    For subscribers

Latest news

  • Top news from MedWatch this week – 31 Mar
  • CHMP recommends nine drugs in March – 31 Mar
  • Coloplast challenges its biggest catheter competitor in clinical contest – 31 Mar
  • Former Bavarian Nordic chairman sees opportunities in Johnson & Johnson's RSV exit – 31 Mar
  • Former GN chair says there have been no acquisition signs from Demant owner – 31 Mar
  • Novo Nordisk helps Canada resolve Ozempic issue – 31 Mar
  • New study says AstraZeneca drug rarely leads to RSV mutations – 31 Mar
  • Danish health minister to answer questions about Novo Nordisk sponsorship of patient group – 30 Mar
  • Bluebird Bio expects delay on FDA sickle cell drug application – 30 Mar
  • WHO mulls over labeling obesity drugs as essential medicines – 30 Mar
See all

Jobs

  • Head of Pharmacovigilance, QPPV

  • Manager QC - Microbiology or Biochemistry

  • Head of Regulatory Affairs

  • Director, Oncology and Translational Science

  • Director/Senior Director, Commercial Excellence

  • Senior Data Manager

  • Nordic Brand Manager

  • Senior IM Process Specialist Medico, CARMO

  • Procurement Manager, Indirect Materials

  • Regulatory Affairs Specialist

  • Senior Automation Engineer & Technical Lead, I2R

  • International & Partnership Manager

  • Manager QC Raw Materials

  • Nordic Medical Advisor

  • System Engineer Medical Device

  • Key Partnership Development Manager

  • Director Regulatory Affairs

  • Technologist / Senior Technologist

  • Research Scientist, 2-year position

  • In-house QA Consultant

  • Senior consultant dentist for the maxillofacial surgery department at Rigshospitalet

  • Good Clinical Practice (GCP) inspectors for the Danish Medicines Agency

  • Corporate QA Specialist, Missionpharma

  • Lead Data Architect

  • Experienced Patent Counsel

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

  • About MedWatch

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge